Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Current Deferred Revenue (2022 - 2025)

Zymeworks' Current Deferred Revenue history spans 3 years, with the latest figure at $93000.0 for Q3 2023.

  • For Q3 2023, Current Deferred Revenue fell 99.72% year-over-year to $93000.0; the TTM value through Sep 2023 reached $93000.0, down 99.72%, while the annual FY2022 figure was $2.4 million, 92.86% down from the prior year.
  • Current Deferred Revenue for Q3 2023 was $93000.0 at Zymeworks, down from $17.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $32.9 million in Q4 2021 and bottomed at $93000.0 in Q3 2023.
  • The 3-year median for Current Deferred Revenue is $10.1 million (2022), against an average of $14.7 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 92.86% in 2022 before it plummeted 99.72% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $32.9 million in 2021, then tumbled by 92.86% to $2.4 million in 2022, then plummeted by 96.05% to $93000.0 in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Current Deferred Revenue are $93000.0 (Q3 2023), $17.8 million (Q2 2023), and $2.4 million (Q1 2023).